Lawsuits have been filed alleging a link between the drug Dupixent and an increased risk of cutaneous T-cell lymphoma, a type of cancer. The lawsuits claim that the manufacturer failed to adequately warn about this potential side effect. The cases have been consolidated in a multidistrict litigation, with some outlets providing information on potential settlements and investigations into the matter.